European Medicines Agency estimated risk of developing a venous thromboembolism (VTE) in a year according to type of combined hormonal contraception (CHC) used212
| Type of CHC used | Risk of developing a VTE in a year (incidence in 10 000 women) |
| Women not using combined hormonal pill/patch/ring and not pregnant | ∼2 |
| Women using CHC containing levonorgestrel, norethisterone or norgestimate | ∼5–7 |
| Women using CHC containing etonogestrel or norelgestromin | ∼6–12 |
| Women using CHC containing drospirenone, gestodene or desogestrel* | ∼9–12 |
Evidence suggests that co-cyprindiol is associated with similar VTE risk to combined oral contraceptive containing drospirenone, gestodene or desogestrel.230